Journal of Drug Discovery And Therapeutics http://jddt.in/index.php/jddt <p>&nbsp;</p> <hr> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;"><span style="text-align: justify;"><strong>Journal of Drug Discovery and Therapeutics (JDDT)</strong> is an international, peer-reviewed, open access, online journal dedicated to the rapid publication of full-length original research papers, short communications, invited reviews, Case studies and editorial commentary and news, Opinions &amp; Perspectives and Book Reviews written at the invitation of the Editor in all areas of the Biomedical and Pharmaceutical Sciences.</span></span></span></p> <hr> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;"><strong>Medical || Dentistry || Biomedical Sciences&nbsp;|| Ayurveda&nbsp;|| Homeopathy&nbsp;||&nbsp;</strong></span></span></p> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;">Anatomy, Physiology, Biochemistry, Molecular Biology, Cell biology, Genetics, Hematology, Pathology, Immunology, Microbiology, Virology, Parasitology, Surgery, Dental Sciences, Sports Physiology,&nbsp;Histopathology, Toxicology and all major disciplines of Biomedical Sciences.</span></span></p> <hr> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;"><strong>Pharmaceutical Sciences || Allied Sciences&nbsp;</strong></span></span></p> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;">Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy and Phytochemistry, Pharmacology and Toxicology, Pharmaceutical and Biomedical Analysis, Clinical Research, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology and all major disciplines of Pharmaceutical&nbsp; Sciences.</span></span></p> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;">Articles are published as they are accepted and are freely available on the journal’s website to facilitate rapid and broad dissemination of research findings to a global audience.</span></span></p> <hr> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;"><strong>Top Reasons for publication with us</strong></span></span></p> <hr> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;"><strong>Quick Quality Review:</strong> The journal has strong international team of editors and reviewers, Rapid Decision and Publication</span></span></p> <hr> <p style="text-align: justify;">&nbsp;</p> Innovative Library en-US Journal of Drug Discovery And Therapeutics 2320-4230 TARGETING CYCLIN B1 WITH ANTISENSE OLIGONUCLETOTIDES- COATED SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES http://jddt.in/index.php/jddt/article/view/444 <p>Antisense oligonucleotides (ASO) represent an attractive trend as specific targeting molecules but sustain poor cellular uptake meanwhile superparamagnetic iron oxide nanoparticles (SPIONs) offer stability of ASO and improved cellular uptake. In the present work we aimed to functionalize SPIONs with ASO targeting the mRNA of Cyclin B1 which represents a potential cancer target and to explore its anticancer activity. For that purpose, four different SPIONs-ASO conjugates, S-M (1–4), were designated depending on the sequence of ASO and constructed by crosslinking carboxylated SPIONs to amino labeled ASO. The impact of S-M (1–4) on the level of Cyclin B1, cell cycle, ROS and viability of the cells were assessed by flowcytometry. The results showed that S-M3 and S-M4 reduced the level of Cyclin B1 by 35 and 36%, respectively. As a consequence to downregulation of Cyclin B1, MCF7 cells were shown to be arrested at G2/M phase (60.7%). S-M (1–4) led to the induction of ROS formation in comparison to the untreated control cells. Furthermore, S-M (1–4) resulted in an increase in dead cells compared to the untreated cells and SPIONs-treated cells. In conclusion, targeting Cyclin B1 with ASO-coated SPIONs may represent a specific biocompatible anticancer strategy.</p> Hosam Zaghloul Doaa A. Shahin Ibrahim El- Dosoky Mahmoud E. El-awady Fardous F. El-Senduny Nashwa K. Abousamra Farid A. Badria ##submission.copyrightStatement## 2018-10-24 2018-10-24 6 10 10.32553/jddt.v6i10.444